Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.38 |
| ▸ | LSS | P48449 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 3/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10526727 | 1.00 | LMNA (0.41) | LMNAZDHHC7DNM1TSHRTHRB | |
| SCHEMBL11641249 | 1.00 | LMNA (0.41) | LMNAZDHHC7DNM1TSHRTHRB | |
| SCHEMBL17509529 | 1.00 | LMNA (0.41) | LMNAZDHHC7DNM1TSHRTHRB | |
| SCHEMBL7431156 | 1.00 | LMNA (0.41) | LMNAZDHHC7DNM1TSHRTHRB | |
| SCHEMBL22207425 | 1.00 | LMNA (0.41) | LMNAZDHHC7DNM1TSHRTHRB | |
| SCHEMBL10555139 | 1.00 | LMNA (0.41) | LMNAZDHHC7DNM1TSHRTHRB | |
| SCHEMBL9716390 | 1.00 | LMNA (0.41) | LMNAZDHHC7DNM1TSHRTHRB | |
| SCHEMBL7440456 | 1.00 | LMNA (0.41) | LMNAZDHHC7DNM1TSHRTHRB | |
| SCHEMBL22207114 | 1.00 | LMNA (0.41) | LMNAZDHHC7DNM1TSHRTHRB | |
| SCHEMBL28920649 | 1.00 | LMNA (0.41) | LMNAZDHHC7DNM1TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937650-B1 | HETEROCYCLIC COMPOUNDS | S BIO PTE LTD (SG) | 2011-06-15 | — | — | EP | claimed |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S'BIO PTE LTD (SG) | 2010-04-22 | — | — | US | claimed |
| EP-2131840-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S*Bio Pte Ltd (SG) | 2009-12-16 | — | — | EP | claimed |
| US-20090048300-A1 | Heterocyclic Compounds | S*BIO PTE LTD. (SG) | 2009-02-19 | — | — | US | claimed |
| WO-2008108741-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S*BIO PTE LTD (SG) | 2008-09-12 | — | — | WO | claimed |
| EP-1937650-A1 | HETEROCYCLIC COMPOUNDS | S*Bio Pte Ltd (SG) | 2008-07-02 | — | — | EP | claimed |
| WO-2007030080-A1 | HETEROCYCLIC COMPOUNDS | S*BIO PTE LTD (SG) | 2007-03-15 | — | — | WO | claimed |
| EP-4382546-A1 | POLY(UREA-URETHANE) POLYMER | BASF SE (DE) | 2024-06-12 | — | — | EP | disclosed |
| WO-2024105027-A1 | CLOSED LOOP RECYCLING CONCEPT FOR COMPOSITES COMPRISING COVALENT ADAPTABLE POLY(UREA-URETHANE) NETWORKS WITH DYNAMIC HINDERED UREA BONDS | BASF SE (DE) | 2024-05-23 | — | — | WO | disclosed |
| CN-117964834-A | Polyacrylate polymers | 巴斯夫欧洲公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2024061814-A1 | CONDITIONER WITH IMPROVED MANAGEABILITY | WELLA GERMANY GMBH (DE) | 2024-03-28 | — | — | WO | disclosed |
| EP-4342444-A1 | CONDITIONER WITH IMPROVED MANAGEABILITY | Wella Germany GmbH (DE) | 2024-03-27 | — | — | EP | disclosed |
| EP-4334373-A1 | TRIAZINE BASED ULTRAVOLET ABSORPTION POLYMER | BASF SE (DE) | 2024-03-13 | — | — | EP | disclosed |
| EP-2131840-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S*Bio Pte Ltd (SG) | 2009-12-16 | — | — | EP | disclosed |
| US-20090048300-A1 | Heterocyclic Compounds | S*BIO PTE LTD. (SG) | 2009-02-19 | — | — | US | disclosed |
| WO-2008108741-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S*BIO PTE LTD (SG) | 2008-09-12 | — | — | WO | disclosed |
| EP-1937650-A1 | HETEROCYCLIC COMPOUNDS | S*Bio Pte Ltd (SG) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007030080-A1 | HETEROCYCLIC COMPOUNDS | S*BIO PTE LTD (SG) | 2007-03-15 | — | — | WO | disclosed |
| EP-0314735-A1 | LIQUID CRYSTAL MATERIAL | THE GENERAL ELECTRIC COMPANY, p.l.c. (GB) | 1989-05-10 | — | — | EP | disclosed |
| WO-1988008870-A1 | LIQUID CRYSTAL MATERIAL | THE GENERAL ELECTRIC COMPANY, P.L.C. (GB) | 1988-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048300-A1 | Heterocyclic Compounds | HDAC1, HDAC3, HDAC11 | LMNA 875/4885ZDHHC7 958/4885DNM1 2396/4885 |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | PAICS, HDAC5, HDAC4 | LMNA 3157/4885ZDHHC7 1055/4885DNM1 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.